Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Amebiasis Market From 2025 to 2034?

The market for amebiasis has seen substantial growth in recent years. There’s anticipated growth from $0.82 billion in 2024 to $0.88 billion in 2025, marking a compound annual growth rate (CAGR) of 6.9%. The historical growth can be credited to factors such as the surge in amoebic infections in tropical areas, underdeveloped sanitation and hygiene measures in emerging nations, increased global travel, particularly to endemic regions, growing understanding of the disease, and the shortage of clean drinking water in rural communities.

The amebiasis market is expected to experience significant expansion in the upcoming years, reaching a value of $1.14 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%. This growth during the forecasted period can be ascribed to factors such as the rising number of immune-compromised patients, escalated governmental efforts to enhance sanitation and health infrastructure, and soaring investments in research for novel treatments. There’s also a heightened emphasis on health initiatives aimed at tackling parasitic ailments and the mounting demand for successful oral drugs. Key trends for the forecasted period include the increased use of combination therapies, creation of vaccines, advancements in the delivery of drugs, progressive strides in pharmaceutical research, and the launch of innovative antiprotozoal drugs.

What Factors Are Propelling the Growth of the Amebiasis Market from 2025 to 2034?

The growth of the amebiasis market is anticipated to be fuelled by the rising incidences of parasitic infections. The terms ‘parasitic infections’ encompass diseases induced by parasites such as protozoa, helminths, or ectoparasites, which exist on or within a host and subsist at the cost of the host. Factors like increased travel, climate change, lack of sanitation, and development of drug resistance contribute to the spread and sustenance of these infections, leading to a rise in their instances. The entamoeba histolytica parasite that results in amebiasis plays a considerable role in propagating parasitic infections by infesting the intestines. Symptoms such as diarrhea, abdominal discomfort, and potentially serious complications like tissue damage and liver abscesses are the outcome of this infestation. The Animal and Plant Health Agency, a UK government agency, stated in January 2024 that in 2022, 1,071 diagnoses of Parasitic Gastroenteritis (PGE) were registered, which incorporated 190 cases of haemonchosis and 95 nematodirosis cases. The count of haemonchosis cases in 2022 had risen notably from the prior year. Consequently, the amebiasis market is being catapulted by the rising instances of parasitic infections. The Augmentation Of The Market Due To The Impact Of Substandard Sanitation

Get Your Free Sample of the Global Amebiasis Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21094&type=smp

What Are the Key Industry Players Leading the Charge in the Amebiasis Market’s Growth?

Major companies operating in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., Zydus Lifesciences Limited

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Amebiasis Market?

Leading entities in the amebiasis market are putting their efforts towards creating improved solutions like ready-to-use oral liquid metronidazole, aiming to benefit patient convenience and the effectiveness of treatment. This ready-to-use oral liquid metronidazole is a pre-mixed liquid variant of the antibiotic applied for treating infections such as amebiasis and is especially beneficial for those with difficulties in pill ingestion. In November 2023, Kesin Pharma Corporation, a pharmaceutical organization in the U.S, attained approval from the U.S Food and Drug Administration for their product Likmez (metronidazole) oral suspension, having a composition of 500 mg/5 mL. This marked the advent of the first ready-to-use oral liquid formula of metronidazole. The formulation of this oral suspension provides an option that is easily accepted by children, simplifies accurate dosing, and assures a more efficient adherence to treatment procedures. Its liquid form provides adaptability in dosage, which empowers health care providers to adjust the treatment as per the distinctive necessities of each patient, particularly with regards to variance in the severity of the infection.

Get Instant Access to the Global Amebiasis Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/amebiasis-global-market-report

Which Growth-Oriented Segments of the Amebiasis Market Are Leading the Industry’s Development?

The amebiasis market covered in this report is segmented –

1) By Type: Metronidazole, Paromomycin, Tinidazole

2) By Route Of Administration: Oral, Intravenous

3) By Application: Hospital, Pharmacy

Subsegments:

1) By Metronidazole: Oral Metronidazole, Intravenous Metronidazole, Combination Therapy with Metronidazole

2) By Paromomycin: Oral Paromomycin, Paromomycin in Combination with Other Drugs

3) By Tinidazole: Oral Tinidazole, Tinidazole for Severe Infections

What Regions Are Influencing the Dynamics of the Amebiasis Market?

North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amebiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Elements Shape the Definition of the Amebiasis Market?

Amebiasis refers to an intestinal infection caused by the parasite Entamoeba histolytica, often leading to symptoms such as diarrhea, abdominal pain, and sometimes liver abscesses. It is used for the treatment of this infection through medications such as metronidazole and tinidazole, which target the parasite in the gut and tissues.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis B Virus (HBV) Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Viral Hepatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Global Cough And Cold Preparations Global Market Report 2025

https://thebusinessresearchcompany.com/report/cough-and-cold-preparations-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: